As of 11:39:08 AM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | -- | 2 | 2 |
| Avg. Estimate | -0.19 | 0 | -0.9 | -0.38 |
| Low Estimate | -0.26 | 0 | -1 | -0.41 |
| High Estimate | -0.13 | 0 | -0.8 | -0.36 |
| Year Ago EPS | -0.35 | -0.23 | -1.32 | -0.9 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | -- | 2 | 2 |
| Avg. Estimate | -- | -- | -- | 3.5M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 7M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | -- | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.31 | -0.35 | -0.36 | -0.25 |
| EPS Actual | -0.35 | -0.23 | -0.25 | -0.27 |
| Difference | -0.04 | 0.12 | 0.11 | -0.03 |
| Surprise % | -12.90% | 34.75% | 31.19% | -10.20% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.19 | 0 | -0.9 | -0.38 |
| 7 Days Ago | -0.19 | 0 | -0.87 | -0.62 |
| 30 Days Ago | -0.19 | 0 | -0.87 | -0.62 |
| 60 Days Ago | -0.19 | 0 | -0.87 | -0.62 |
| 90 Days Ago | -0.19 | 0 | -0.87 | -0.62 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | 1 | -- | 1 | 1 |
| Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| VIRX | 44.29% | -- | 31.82% | 57.22% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Downgrade | Rodman & Renshaw: Buy to Neutral | 12/27/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 11/14/2024 |
| Downgrade | Leerink Partners: Outperform to Market Perform | 8/16/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 8/15/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 5/23/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 4/17/2024 |
Related Tickers
CDT Conduit Pharmaceuticals Inc.
0.0717
+4.52%
MTEM Molecular Templates, Inc.
0.0360
-10.00%
VRPX Virpax Pharmaceuticals, Inc.
0.3890
+5.37%
ADTX Aditxt, Inc.
0.1982
+4.43%
ABP Abpro Holdings, Inc.
1.6415
-8.33%
COEP Coeptis Therapeutics Holdings, Inc.
5.16
-6.18%
LYRA Lyra Therapeutics, Inc.
0.2197
+6.44%
VOR Vor Biopharma Inc.
1.1750
+5.86%
CNSP CNS Pharmaceuticals, Inc.
0.1189
-1.25%
MBIO Mustang Bio, Inc.
0.2621
+48.08%